» Articles » PMID: 33446089

Novel Application of Single-cell Next-generation Sequencing for Determination of Intratumoral Heterogeneity of Canine Osteosarcoma Cell Lines

Overview
Date 2021 Jan 15
PMID 33446089
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Osteosarcoma (OSA) is a highly aggressive and metastatic neoplasm of both the canine and human patient and is the leading form of osseous neoplasia in both species worldwide. To gain deeper insight into the heterogeneous and genetically chaotic nature of OSA, we applied single-cell transcriptome (scRNA-seq) analysis to 4 canine OSA cell lines. This novel application of scRNA-seq technology to the canine genome required uploading the CanFam3.1 reference genome into an analysis pipeline (10X Genomics Cell Ranger); this methodology has not been reported previously in the canine species, to our knowledge. The scRNA-seq outputs were validated by comparing them to cDNA expression from reverse-transcription PCR (RT-PCR) and Sanger sequencing bulk analysis of 4 canine OSA cell lines (COS31, DOUG, POS, and HMPOS) for 11 genes implicated in the pathogenesis of canine OSA. The scRNA-seq outputs revealed the significant heterogeneity of gene transcription expression patterns within the cell lines investigated (COS31 and DOUG). The scRNA-seq data showed 10 distinct clusters of similarly shared transcriptomic expression patterns in COS31; 12 clusters were identified in DOUG. In addition, cRNA-seq analysis provided data for integration into the Qiagen Ingenuity Pathway Analysis software for canonical pathway analysis. Of the 81 distinct pathways identified within the clusters, 33 had been implicated in the pathogenesis of OSA, of which 18 had not been reported previously in canine OSA.

Citing Articles

Single-cell T-cell receptor repertoire profiling in dogs.

Hoang M, Skidmore Z, Rindt H, Chu S, Fisk B, Foltz J Commun Biol. 2024; 7(1):484.

PMID: 38649520 PMC: 11035579. DOI: 10.1038/s42003-024-06174-w.


Single-B cell analysis correlates high-lactate secretion with stress and increased apoptosis.

Bucheli O, Rodrigues D, Portmann K, Linder A, Thoma M, Halin C Sci Rep. 2024; 14(1):8507.

PMID: 38605071 PMC: 11009249. DOI: 10.1038/s41598-024-58868-0.


Review of Molecular Technologies for Investigating Canine Cancer.

Kehl A, Aupperle-Lellbach H, de Brot S, van der Weyden L Animals (Basel). 2024; 14(5).

PMID: 38473154 PMC: 10930838. DOI: 10.3390/ani14050769.


Use of cutting-edge RNA-sequencing technology to identify biomarkers and potential therapeutic targets in canine and feline cancers and other diseases.

Choi Y, Nam M, Lee H, Choi K J Vet Sci. 2023; 24(5):e71.

PMID: 38031650 PMC: 10556291. DOI: 10.4142/jvs.23036.


Tumor-associated macrophages: Prognostic and therapeutic targets for cancer in humans and dogs.

Brady R, Thamm D Front Immunol. 2023; 14:1176807.

PMID: 37090720 PMC: 10113558. DOI: 10.3389/fimmu.2023.1176807.


References
1.
Skorupski K, Uhl J, Szivek A, Allstadt Frazier S, Rebhun R, Rodriguez Jr C . Carboplatin versus alternating carboplatin and doxorubicin for the adjuvant treatment of canine appendicular osteosarcoma: a randomized, phase III trial. Vet Comp Oncol. 2013; 14(1):81-7. PMC: 5012431. DOI: 10.1111/vco.12069. View

2.
Kamel W, Sugihara E, Nobusue H, Yamaguchi-Iwai S, Onishi N, Maki K . Simvastatin-Induced Apoptosis in Osteosarcoma Cells: A Key Role of RhoA-AMPK/p38 MAPK Signaling in Antitumor Activity. Mol Cancer Ther. 2016; 16(1):182-192. DOI: 10.1158/1535-7163.MCT-16-0499. View

3.
Sakthikumar S, Elvers I, Kim J, Arendt M, Thomas R, Turner-Maier J . Is Recurrently Mutated in Whole-Exome Sequenced Canine Osteosarcoma. Cancer Res. 2018; 78(13):3421-3431. DOI: 10.1158/0008-5472.CAN-17-3558. View

4.
Thamm D, OBrien M, Vail D . Serum vascular endothelial growth factor concentrations and postsurgical outcome in dogs with osteosarcoma. Vet Comp Oncol. 2009; 6(2):126-32. DOI: 10.1111/j.1476-5829.2007.00153.x. View

5.
Wu J, Cui L, Yuan J, Wang Y, Song S . Clinical significance of the phosphorylation of MAPK and protein expression of cyclin D1 in human osteosarcoma tissues. Mol Med Rep. 2017; 15(4):2303-2307. DOI: 10.3892/mmr.2017.6224. View